539 Depletion of soluble PD-L1 with engineered NaNot® nanoparticles promotes antitumor immunity

• Xin Liu,
• Haidong Dong,
• Sean Park,
• Curtis Ruegg,
• Fabrice Lucien-Matteoni,
• Michelle Hsu,
• Jacob Hirdler,
• Roxane Lavoie,
• Kevin Pavelko,
• Jacob Orme,
• Lou Hawthorne,
• John Dodgson

Affiliations

Xin Liu

Keck School of Medicine, University of Southern California, Los Angeles, California, USA

Haidong Dong

Mayo Clinic, Rochester, MN, USA

Sean Park

Department of Medicine, Faculty of Health Sciences, McMaster University, Hamilton, Ontario, Canada

Curtis Ruegg

6Amphivena Therapeutics, South San Francisco, CA, USA

Fabrice Lucien-Matteoni

Mayo Clinic, Rochester, MN, USA

Michelle Hsu

Mayo Clinic, Rochester, MN, USA

Jacob Hirdler

Mayo Clinic, Rochester, MN, USA

Roxane Lavoie

1Mayo Clinic, Rochester, MN, USA

Kevin Pavelko

1Mayo Clinic, Rochester, MN, USA

Jacob Orme

1Mayo Clinic, Rochester, MN, USA

Lou Hawthorne

2NaNotics LLC, Mill Valley, CA, USA

John Dodgson

2NaNotics LLC, Mill Valley, CA, USA